热门资讯> 正文
Anixa Biosciences与克利夫兰诊所执行数据传输协议
2025-11-05 21:58
- Anixa Biosciences (ANIX) on Wednesday said that it has executed a data transfer agreement with the Cleveland Clinic as a key step in the process of transferring the breast cancer vaccine clinical trial data and sponsorship to Anixa for future clinical development.
- With enrollment completed and encouraging immune response data observed in the Phase 1 trial, Anixa plans to advance the vaccine into a Phase 2 clinical trial and will assume full sponsorship of the IND.
- The IND, currently sponsored by Cleveland Clinic, is in the process of being transferred to Anixa.
- The DTA will allow for the transfer of all relevant data and information, collected and generated from the Phase 1 clinical trial, to Anixa.
More on Anixa Biosciences
- Anixa Biosciences announces issuance of additional U.S. patent for CAR-T technology
- Seeking Alpha’s Quant Rating on Anixa Biosciences
- Historical earnings data for Anixa Biosciences
- Financial information for Anixa Biosciences
推荐文章
一周财经日历 | 美联储新主席“呼之欲出”！特朗普下周或提前公布；年末新股上市潮！卧安机器人、英矽智能等6只新股招股中
年终盘点 | 26年投资展望！美股有哪些经济大事？
年终盘点 | 2025年港美股十大飙升ETF：年内暴涨620%！Palantir多头杠杆ETF成年度黑马
年终盘点 | 2025年港股牛股、妖股、熊股名单出炉！这家公司飙升超33倍后跌落神坛
华盛早报 | 科技股强劲反弹！纳指一度涨超2%；哈塞特称仍有很大的降息空间
年终盘点 | 美股七巨头从“集体狂飙”到“残酷分化”！谁能在2026年继续坐庄？
打新攻略 | 2025港股IPO收官战！6只招股+9只待上市+6只聆讯！打新资金如何巧妙“吃大肉”？
年末货币政策“压轴大戏”：欧洲四央行同日登场，仅一家有望降息？
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
